DBVTF News and Press, Dbv Techs Boulogne Bill From 10/05/21

Baker Brothers’ 13F portfolio value decreased from $23.07B to $22.77B this quarter. The InVitae stake was reduced this quarter while increasing Apellis Pharma and Heron Therapeutics. The top three positions are Seagen, BeiGene, and Incyte Corporation and they add up to almo...

DBV Technologies S.A. (DBVT) Q2 2021 Earnings Conference Call August 02, 2021 05:00 PM ET Company Participants Anne Pollak - Head of Investor Relations Daniel Tassé - Chief Executive Officer Sébastien Robitaille - Chief Financial Officer Conference Call Participants Graig Suvannavej...

Baker Brothers’ 13F portfolio value decreased from $26.54B to $23.07B this quarter. The large stake in Alexion Pharmaceuticals was decreased during the quarter. The top three positions are Seagen, BeiGene, and Incyte Corporation and they add up to almost ~57% of the portfol...

DBV Technologies S.A. (DBVT) Q4 2020 Earnings Conference Call March 11, 2021 5:00 PM ET Company Participants Anne Pollak - Head of Investor Relations Daniel Tassé - Chief Executive Officer & Director Pascal Wotling - Chief Technical Operations Officer Pharis Mohideen - Chief Medical ...

COVID-19 Is Distracting Investors from an Amazing Market Opportunity While the world remains hyper-focused on COVID-19 as the biggest healthcare challenge of the past century, it is perhaps easy to overlook progress being made to treat more mundane (yet far more durable) medical problems. ...

Aimmune Gets a Boost as FDA Green Signals Allergy Medication Aimmune Therapeutics ( AIMT ) received FDA nod for its peanut allergy medication Palforzia. This orally administered medication aims to mitigate allergic reactions caused by exposure to peanuts. While it is not designed to be an ...